Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
NCT03283228 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2017-09-14
Summary
1. Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.
2. Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.
Conditions
- Adult Acute Myeloid Leukemia
Interventions
- DIAGNOSTIC_TEST
-
Cd11b and Cd56 markers
The expression of CD11b and CD56 in newly diadnosed cases of AML
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-12-01
- Primary Completion
- 2018-12-01
- Completion
- 2019-10-01
More Related Trials
-
Prognostic Value of CD318 in AML at Assiut University Hospital.
NCT04708444 ·Status: UNKNOWN
-
Biomarkers in Patients With Acute Myeloid Leukemia
NCT01138319 ·Status: COMPLETED
-
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
NCT03298984 ·Status: COMPLETED ·Phase: PHASE1
-
Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia
NCT01284010 ·Status: COMPLETED
-
Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia
NCT00003861 ·Status: ACTIVE_NOT_RECRUITING
-
Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia: a Prospective Multicentric Study.
NCT04311060 ·Status: NOT_YET_RECRUITING
-
S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy
NCT01360125 ·Status: COMPLETED
-
Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia
NCT01138306 ·Status: COMPLETED
-
Biomarker Study in Tissue Samples From Patients With Acute Myeloid Leukemia
NCT01232842 ·Status: COMPLETED
-
SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT05445154 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
NCT00788892 ·Status: COMPLETED ·Phase: PHASE2
-
Description and Prognostic Evaluation of Four Biological Parameters of Blast Cells in Adult Acute Lymphoblastic Leukemia
NCT00188084 ·Status: UNKNOWN
-
Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT01229956 ·Status: COMPLETED
-
Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia
NCT03234985 ·Status: COMPLETED
-
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies
NCT06387082 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720
NCT01004965 ·Status: COMPLETED
-
Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia
NCT01057290 ·Status: COMPLETED
-
Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia
NCT01642121 ·Status: COMPLETED
-
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
NCT02326584 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
NCT02859948 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60
NCT04083911 ·Status: UNKNOWN ·Phase: PHASE3
-
CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT05654779 ·Status: TERMINATED ·Phase: PHASE1
-
Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia
NCT01505699 ·Status: COMPLETED
-
Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia
NCT05893836 ·Status: COMPLETED
-
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
NCT02293993 ·Status: COMPLETED ·Phase: PHASE1